1,573 results on '"Senan, S."'
Search Results
152. Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
153. ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
154. OC-0068 MR-guided adaptive radiotherapy for intra-abdominal lymphoma
155. PO-0981 Role of on-table plan adaptation in MRguided ablative radiation therapy for central lung tumors
156. OA06.04 Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial.
157. Magnetic Resonance (MR)-Guided Adaptive Stereotactic Ablative Radiotherapy for Adrenal Metastases
158. Radiation Therapy for Superior Sulcus Tumor
159. Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score-Adjusted Studies
160. Optimal Imaging Follow-up Schedules after Stereotactic Ablative Radiotherapy for Early Non-Small-Cell Lung Cancer: Findings of an International Delphi Consensus Study
161. Estimated Benefit of Dose Reduction to Highly Ventilated Lung Regions for Stage III Non-small Cell Lung Cancer Patients Using Normal Tissue Complication Probability Models
162. Treatment-Related Toxicity in Patients with Early Stage Non-Small Cell Lung Cancer and Co-Existing Interstitial Lung Disease: A Systematic Review
163. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
164. Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial
165. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
166. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
167. Patient reported outcomes after the treatment of early stage non-small cell lung cancer by stereotactic body radiotherapy compared to surgery
168. Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches
169. (P36) Stereotactic MRI-Guided Adaptive Radiotherapy for Adrenal Metastases
170. PO-0746: NTCP modelling of pulmonary toxicity after stereotactic radiotherapy for central lung tumors
171. OC-0519: Radiotherapy plan quality using a double focused, double stacked multi-leaf collimator
172. OC-0185: SBRT using MR-guided, video-assisted gated treatment delivery during patient breath holds
173. PV-0038: Esophagus toxicity after stereotactic radiotherapy of central lung tumor: NTCP modelling
174. Treatment Of Malignant Intracranial Germ Cell Tumours
175. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
176. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
177. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
178. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
179. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy (SABR) for Lung Cancer: Physician Performance Versus Radiomic Assessment
180. Risks of Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer With Co-Existing Interstitial Lung Disease: A Systematic Review of Literature
181. Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up : 2nd ESMO Consensus Conference on Lung Cancer
182. Kankerzorg in beeld: de oudere patiënt
183. 1. MR-guided adaptive stereotactic radiotherapy: A new paradigm in radiotherapy
184. Identifying Barriers to Accrual in Radiation Oncology Randomized Trials
185. OA 16.01 Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score-Adjusted Studies
186. P2.14-019 Magnetic Resonance (MR)-Guided Adaptive Stereotactic Ablative Radiotherapy for Adrenal Metastases
187. MS 11.04 Radiation Therapy for Superior Sulcus Tumor
188. Conditional Survival Probabilities Following Stereotactic Body Radiation Therapy for Early-Stage Non-small Cell Lung Cancer
189. Impact of Daily Adaptive Plans for Stereotactic MR-Guided Radiation Therapy (SMART) in Early Stage Lung Cancer
190. Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-Analysis of Propensity Score-Adjusted Comparative Effectiveness Studies
191. Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Tumors
192. Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer
193. Role of Daily Plan Adaption during Breath-Hold MR-Guided Stereotactic Ablative Radiotherapy for Adrenal Metastases
194. Identifying Barriers to Accrual in Radiation Oncology Randomized Trials: Insights From a Trial of Stereotactic Radiation for Oligometastatic Disease
195. Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry
196. SP-0494: Using a MRI-guided radiation therapy system for prostate cancer patients
197. OC-0425: Clinical experience with stereotactic MR-guided adaptive radiation therapy for pancreatic tumors
198. OC-0161: patient tolerance of stereotactic MR-guided adaptive radiation therapy: an assessment using PRO’s
199. PV-0238: Use of Stereotactic Ablative Radiotherapy in Non-Small Cell Lung Cancer Measuring 5 cm or More
200. OC-0490: A robust and fast planning approach for adaptive MR-guided treatment of pancreatic cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.